Lung Adenocarcinoma with Paraneoplastic Hyper-Eosinophilia Not Responding To Pembrolizumab.

IF 0.9 Q4 RESPIRATORY SYSTEM Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine Pub Date : 2021-07-31 eCollection Date: 2021-01-01 DOI:10.1177/11795484211030164

Hisham Wehbe, Maria Kozah, Salwa A Koubaissi

{"title":"Lung Adenocarcinoma with Paraneoplastic Hyper-Eosinophilia Not Responding To Pembrolizumab.","authors":"Hisham Wehbe, Maria Kozah, Salwa A Koubaissi","doi":"10.1177/11795484211030164","DOIUrl":null,"url":null,"abstract":"Background: Paraneoplastic hyper-eosinophilia associated with metastatic lung adenocarcinoma is a rare finding and has been associated with a poor prognosis when present. Early hyper-eosinophilia appearing following non-small cell lung cancer (NSCLC) treatment with immune checkpoint inhibitors (ICI) has been previously reported with contradictory outcomes.Case summary: We present the case of an elderly man with newly diagnosed metastatic lung adenocarcinoma and baseline hyper-eosinophilia, treated with pembrolizumab, and showing evidence of significant and rapid disease progression suggestive of hyper-progressive disease, worsening baseline hyper-eosinophilia, and a fatal outcome within 1 month of therapy initiation.Conclusion: Pre-treatment hyper-eosinophilia could represent a predictive factor of an unfavorable response to ICI treatment in cases of NSCLC. Additional similar cases are needed to draw a more conclusive relationship.","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":" ","pages":"11795484211030164"},"PeriodicalIF":0.9000,"publicationDate":"2021-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11795484211030164","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11795484211030164","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 4

Abstract

Background: Paraneoplastic hyper-eosinophilia associated with metastatic lung adenocarcinoma is a rare finding and has been associated with a poor prognosis when present. Early hyper-eosinophilia appearing following non-small cell lung cancer (NSCLC) treatment with immune checkpoint inhibitors (ICI) has been previously reported with contradictory outcomes.

Case summary: We present the case of an elderly man with newly diagnosed metastatic lung adenocarcinoma and baseline hyper-eosinophilia, treated with pembrolizumab, and showing evidence of significant and rapid disease progression suggestive of hyper-progressive disease, worsening baseline hyper-eosinophilia, and a fatal outcome within 1 month of therapy initiation.

Conclusion: Pre-treatment hyper-eosinophilia could represent a predictive factor of an unfavorable response to ICI treatment in cases of NSCLC. Additional similar cases are needed to draw a more conclusive relationship.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

伴副肿瘤性嗜酸性粒细胞增多的肺腺癌对派姆单抗无反应。

背景:伴转移性肺腺癌的副肿瘤性嗜酸性细胞增多症是一种罕见的发现，出现时预后较差。免疫检查点抑制剂(ICI)治疗非小细胞肺癌(NSCLC)后出现的早期嗜酸性粒细胞增多症先前报道的结果相互矛盾。病例总结:我们报告了一例新诊断的转移性肺腺癌和基线嗜酸性粒细胞增多症的老年男性患者，接受派姆单抗治疗，并显示出明显和快速的疾病进展，提示疾病的超进展，基线嗜酸性粒细胞增多症恶化，并在治疗开始后1个月内死亡。结论:治疗前嗜酸性粒细胞增多可能是非小细胞肺癌对ICI治疗不良反应的一个预测因素。需要更多类似的案例来得出更确凿的关系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊